EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Is Aripiprazole an Effective Adjunct to Reduce Metabolic Adverse Effects Caused by Clozapine in Patients With Schizophrenia—A Systematic Review

Avtaar Singh iD, Soban Sadiq iD

Neuropsychopharmacology Reports · 2026

DOI: 10.1002/npr2.70149 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neuropsychopharmacology Reports, 2026. Verfasst von Avtaar Singh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Kent and Medway Medical School, University of Kent, Canterbury, UK. Hauptthemen laut MEDLINE: Aripiprazole, Schizophrenia, Clozapine, Antipsychotic Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clozapine is an atypical antipsychotic used in the treatment of schizophrenia. However, its use is associated with significant metabolic adverse effects, including hyperglycaemia, dyslipidaemia, and weight gain. Aripiprazole, a newer atypical antipsychotic with a different pharmacological profile, has been suggested to mitigate some of these metabolic side effects when used adjunctively. This systematic review assessed the evidence for the effectiveness of adjunctive Aripiprazole in reducing clozapine‐induced metabolic adverse effects. A systematic search was conducted across five academic databases, resulting in 52 articles. Following inclusion and exclusion criteria, eight studies were selected for narrative synthesis. These included randomized controlled trials, cohort studies, and case reports. The key metabolic outcomes assessed were glucose levels, lipid profiles, body weight, and waist circumference. Adjunctive Aripiprazole was associated with improvements in LDL and total cholesterol levels, as well as reductions in body weight in several studies. Fasting glucose levels and waist circumference showed limited or inconsistent changes. The overall evidence remains limited, particularly in terms of high‐quality, long‐term trials. This review suggests that Aripiprazole may offer some benefit in managing clozapine‐induced dyslipidaemia and weight gain. However, variability in outcomes, study design, and patient characteristics highlight the need for further research. Future studies should focus on larger, longer duration trials, broader patient demographics, and optimal dosing strategies to better evaluate the clinical utility of this combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazoleSchizophreniaClozapineAntipsychotic AgentsMetabolic DiseasesHumansWeight GainDrug Therapy, Combination

Stichwörter der Autor:innen

antipsychoticsaripiprazoleclozapinemetabolic syndromeschizophrenia

Substanzen

AripiprazoleClozapineAntipsychotic Agents

Autor:innen und Institutionen

  • Kent and Medway Medical School, University of Kent, Canterbury, UK.

ORCID-Profile: Avtaar Singh, Soban Sadiq

Zitieren

APA

Singh, A., & Sadiq, S. (2026). Is Aripiprazole an Effective Adjunct to Reduce Metabolic Adverse Effects Caused by Clozapine in Patients With Schizophrenia—A Systematic Review. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.70149

Vancouver

Singh A, Sadiq S. Is Aripiprazole an Effective Adjunct to Reduce Metabolic Adverse Effects Caused by Clozapine in Patients With Schizophrenia—A Systematic Review. Neuropsychopharmacology Reports. 2026. doi:10.1002/npr2.70149

BibTeX
@article{Singh2026,
  author = {Singh, Avtaar and Sadiq, Soban},
  title = {Is Aripiprazole an Effective Adjunct to Reduce Metabolic Adverse Effects Caused by Clozapine in Patients With Schizophrenia—A Systematic Review},
  journal = {Neuropsychopharmacology Reports},
  year = {2026},
  doi = {10.1002/npr2.70149}
}
Kostenlos starten →